Background: Inflammatory response is known to play a vital role in carcinogenesis and cancer progression. The prognostic relevance of monocyte-to-lymphocyte ratio (MLR), as a biomarker of inflammatory response has been demonstrated in patients with hematologic cancers.
diagnostics and therapeutics, the 5-year survival rate of lung cancer patients remains poor. 3, 4 There may be local recurrence or distant metastasis even after surgical resection. 5 Identification of new prognostic indicators for optimal risk-stratification of lung cancer patients is a key research imperative that can help clinicians to optimize treatment strategy.
Inflammation plays a key role in tumorigenesis and cancer progression. 6 As key players in the inflammatory response, the association of monocytes and lymphocytes with carcinogenesis has been widely investigated. High monocyte-to-lymphocyte ratio (MLR) in peripheral blood was shown to be associated with unfavorable prognosis in patients with hematological malignancies, [7] [8] [9] nasopharyngeal carcinoma, 10 and malignant pleural mesothelioma. 11 To the best of our knowledge, the potential association of MLR with prognosis of lung cancer patients has been investigated only in the context of stage I lung cancer. In this e30 Lab Medicine 2018;49;e29-e39 DOI:10.1093/labmed/lmw049 study, we retrospectively assessed the prognostic significance of MLR in patients with stage I-IIIa lung cancer who underwent radical surgery.
Materials and Methods

Patients
Clinical records of a total of 705 patients with stage I-IIIa lung cancer who underwent radical surgery at Zhejiang Cancer Hospital between October 2006 and January 2011, were retrospectively reviewed. The inclusion criterion was treatment-naive patients with histopathological diagnosis of primary lung cancer who underwent radical resection. Exclusion criteria were recurrent or metastatic cancer, concomitant cancer of any origin, coexisting hematological disorders, active infection, and history of treatment with drugs known to affect hematological system (eg, immunosuppressants, hormones, and colony stimulating factor).
The histological diagnosis was based on the classification criteria for lung cancer published by the World Health Organization (WHO) and the International Association for the Study of Lung Cancer (IASLC). 12 Tumor, node, and metastasis (TNM) staging was performed based on the IASLC staging system. 13 The study protocol was approved by the Institutional Ethics Committee at the Zhejiang Cancer Hospital. Written informed consent was obtained from all patients prior to their enrollment.
Data pertaining to clinicopathological variables and laboratory indices were extracted from medical records. Clinicopathological variables included gender, age, smoking, histological type, tumor differentiation, and TNM staging.
The follow-up evaluation included physical examination and laboratory investigation were performed once every 3 months for the first 2 years, at 6-month intervals for the next 3 years, and at yearly intervals thereafter. The median follow-up period was 40 months, ranging from 1 to 75 months.
Disease-free survival (DFS) was calculated based on the time elapsed from the date of pulmonary resection to detection of local recurrence, distant metastasis or to the date of most recent follow-up. Overall survival (OS) was calculated based on the time elapsed from lung resection to death or to the date of most recent follow-up.
Preoperative investigations were performed within 1 week prior to surgery. Complete blood counts were tested by automated blood cell counting system (XE-2100 Sysmex, Japan). The MLR was defined as the absolute counts of monocytes divided by those of lymphocytes.
Statistical Analyses
Receiver operating characteristic (ROC) curve analysis was performed to ascertain the optimal cutoff values of MLR associated with maximum sensitivity and specificity. 
Results
Characteristics of Patients
Optimal Cutoff Value for MLR
On ROC curve analysis for survival outcomes (Figure 1 ), the ideal cutoff value of MLR was determined to be 0. 
Association Between Clinical Characteristics and MLR
Baseline clinical characteristics of patients disaggregated by preoperative MLR levels are listed in Table 2 . No significant between-group difference was observed between high MLR and low MLR groups with respect to age (P = .287), TNM stage (P = .063), and differentiation (P = .269). However, MLR level showed a correlation with gender (P < .001), smoking (P < .001), and histological type (P = .001).
Prognostic Value of MLR
On Kaplan-Meier analysis and log-rank test, a significant between-group difference was observed in OS and DFS (P < .001 and P = .002, respectively; Figures 2 and 3). Patients with low MLR (≤0.355) exhibited better prognosis than those with high MLR (>0.355). On subgroup analyses, patients with pathological stage I and II tumors with low MLR (≤0.355) had longer OS as compared to their counterparts with high MLR (P = .010, Figure 5 ). However, no significant difference in DFS was observed in this respect (P = .098, Figure 4 ).
Patients with stage IIIa tumors and low MLR had markedly longer DFS and OS as compared to their counterparts with high MLR (P = .013 for DFS, P < .001 for OS; Figures 6 and 7) .
On subgroup analyses by tumor differentiation status (well, moderate, and poor), patients with well differentiated and moderately differentiated tumors with low MLR had longer OS than their counterparts with high MLR (P = .018, Figure 9 ); however, no such difference was observed with respect to DFS (P = .067, Figure 8 ). Patients with poorly differentiated tumors and low MLR had longer DFS and OS than their counterparts with high MLR (P = .014 for DFS, P = .002 for OS; Figures 10 and 11 ).
On subgroup analyses by tumor histological type (squamous cell carcinoma [SCC] and adenocarcinoma), patients with SCC and low MLR had longer DFS and OS than their counterparts with high MLR (P = 0.002 for DFS, P = 0.001 for OS; Figures 12 and 13) . Patients with adenocarcinoma and low MLR had longer OS than their counterparts with high MLR (P = .035, Figure 15) ; however, no such difference was observed with respect to DFS (P = .217, Figure 14 ).
On subgroup analyses by smoking habit (never smoker and smoker), MLR showed no prognostic significance in never smokers (P = .078 for DFS, P = .137 for OS; Figures 16 and  17 ). Smoking patients with low MLR had longer DFS and OS than their counterparts with high MLR (P = .008 for DFS, P = .003 for OS; Figures 18 and 19) . 
Figure 1
The receiver operating characteristic (ROC) curves analysis for the optimal cut-off value of MLR. Variables linked to DFS and OS on univariate and multivariate analyses are shown in Table 3 and 
Discussion
In this study, we investigated the prognostic significance of MLR in a cohort of 705 patients with lung carcinoma. MLR showed an obvious association with patient survival. Although the underlying mechanism of this association is not clear, the characteristics of monocytes and lymphocytes involved in inflammatory and immune responses may provide a possible explanation.
Monocytes and lymphocytes are key players of the inflammatory response, and their role in carcinogenesis has been widely investigated. Previously, the prognostic significance of MLR has been investigated mainly in the context of hematological malignancies. 14, 15 However, recent studies have shown the association of MLR with survival in patients with solid tumors. For example, Tsuyoshi Ozawa et al found MLR to be an important prognostic factor in patients with stage IV colorectal cancer who underwent curative resection. 16 Rou Jiang et al confirmed that preoperative MLR was an independent predictor of metastatic nasopharyngeal carcinoma. 10 However, there was less research for the prognostic significance of MLR in patients with lung cancer.
In this study, we retrospectively reviewed a large cohort of lung cancer patients, and observed an association of high MLR with lower OS and DFS. Our findings are consistent with those reported earlier in the context of hematological malignancy and some solid cancers. To the best of our knowledge, this is the first study to investigate the prognostic implication of MLR in patients with stage I-IIIa lung cancer who underwent radical surgery.
Tumor stage and differentiation degree may influence inflammation response and immune suppression. Therefore, we further stratified patients into subgroups to determine whether MLR was still a predictor of survival when considering tumor stage 
Figure 2
Kaplan-Meier survival curves according to MLR levels for OS. 
Figure 3
Kaplan-Meier survival curves according to MLR levels for DFS.
Figure 4
Kaplan-Meier curve for DFS for stage I, II.
Figure 5
Kaplan-Meier curve for OS for stage I, II.
Figure 6
Kaplan-Meier curve for DFS for stage IIIa.
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Figure 7
Kaplan-Meier curve for OS for stage IIIa.
Figure 8
Kaplan-Meier curve for DFS for well and moderate differentiation.
Figure 9
Kaplan-Meier curve for OS for well and moderate differentiation.
Figure 10
Kaplan-Meier curve for DFS for poor differentiation. 
Figure 11
Kaplan-Meier curve for OS poor differentiation.
Figure 12
Kaplan-Meier curve for DFS for SCC.
Figure 13
Kaplan-Meier curve for OS for SCC.
Figure 14
Kaplan-Meier curve for DFS for adenocarcinoma. 
Figure 15
Kaplan-Meier curve for OS for adenocarcinoma.
Figure 16
Kaplan-Meier curve for DFS for never smoker.
Figure 17
Kaplan-Meier curve for OS for never smoker.
Figure 18
Kaplan-Meier curve for DFS for smoker. may influence tumors differently depending on tumor stage, tumor histology, differentiation status, and tumor microenvironment. 17 Further research is required to elucidate the underlying mechanism.
Lymphocytes and macrophages are elementary components of tumor microenvironment. [18] [19] [20] [21] Lymphocytes are critical for triggering an immune response, 22, 23 while macrophages derived from circulating monocytes may infiltrate tumors and rapidly differentiate into tumor-associated macrophages (TAMs). 24 TAMs are implicated in tumor cell invasion, migration, angiogenesis, and suppression of antitumor immune response by secreting a variety of inflammatory cytokines. These include matrix metalloprotein-9, platelet-derived growth factor, and vascular endothelial growth factor A. [25] [26] [27] [28] [29] Circulating monocytes in blood may indirectly reflect the presence of TAM. 30 On the contrary, lymphocytes play a pivotal role in cell-mediated antitumor immune response. 31, 32 A favorable impact of tumor-infiltrating lymphocytes (TILs) on survival of patients with ovarian and colorectal cancer has been demonstrated. [33] [34] [35] Activated specific CD8+ T-cells are known to suppress tumor growth by virtue of their cytotoxic and pro-apoptotic effect. 36, 37 MLR is an index that incorporates information on both monocytes and lymphocytes, and thus may reflect the status of host immune response mediated via TAM and TIL.
In this study, we selected patients with stage I-IIIa lung cancer; these patients are typically suitable for surgery, while those with stage IIIb and IV lung cancer, by definition, have distant metastasis or local spread to nearby organs, and are typically not suitable for surgery. Although patients with stage I-IIIa had undergone radical surgery, the prognosis of patients tends to vary. Therefore, we included these patients to investigate the prognostic significance of MLR.
Traditionally, TNM stage is the most widely used criteria for prognostic assessment of patients with lung cancer. Our results underline the clinical relevance of use of MLR in addition to the traditional indicators. Use of MLR in clinical settings may aid appropriate risk-stratification and treatment decision-making.
Hematological tests are part of the routine workup of cancer patients, and MLR may serve as a convenient, reliable, inexpensive and highly reproducible prognostic biomarker.
The retrospective design of our study is a key limitation that is liable to introduce selection bias and potentially distort the observed association.
In this study, preoperative MLR was an independent predictor of DFS and OS in lung cancer patients who underwent radical surgery. The combination of MLR, TNM staging, and tumor differentiation may be useful in prognostic assessment in these patients. Large-scale clinical trials are required to verify our results, and further in-depth research is necessary to illuminate the underlying mechanism for this association. LM
